Russian President Vladimir Putin has ordered mass COVID-19 vaccination to start next week in Russia.

Vladimir Putin orders mass vaccinations against COVID-19 from next week in Russia

Covid-19 hospitalizations in the US reached a record 100,000 on Wednesday, straining health-care systems in numerous states. Hospitalisations have set new records almost daily since November 10 in the nation's largest and longest surge. 
 
<a href="https://www.wionews.com/world/vaccines-insufficient-to-prevent-surge-in-coronavirus-for-next-six-months-who-347022">Also read | Vaccines insufficient to prevent surge in coronavirus for next six months: WHO</a> 
 
According to the health experts, the number will continue to climb, as Thanksgiving gatherings and holidays are expected to accelerate an already rampant spread of the virus this fall.&nbsp;

"There are 100,226 people currently hospitalized with COVID-19 in the US — the first time hospitalizations have exceeded 100k," the COVID Tracking Project said in a tweet. 
 
The current number of hospitalized patients underscores the scope and severity of the current phase of the U.S. outbreak. Never before had the number of hospitalized Covid patients surpassed 60,000, according to data compiled by the Covid Tracking Project, which is run by journalists at The Atlantic.

Meanwhile, US officials have said that they expect to have enough vaccine doses to immunize about 100 million higher-risk people by the end of February. 
 
But the World Health Organization does not believe there will be enough quantities of coronavirus vaccines in the next three to six months to prevent a surge of infections, its top emergency expert said.

"We are not going to have sufficient vaccinations in place to prevent a surge in cases for three to six months," Mike Ryan told a social media event, calling on people to maintain social distancing and respect other measures to restrict the spread of COVID-19. 
 
The World Health Organization (WHO) has identified 49 "candidate vaccines" at the stage of clinical trials in humans by mid-November, up from 11 in mid-June.

WHO had received data from Pfizer and BioNTech on the COVID-19 vaccine and was reviewing it for "possible listing for emergency use", a benchmark for countries to authorise national use.

(With inputs from agencies)&nbsp;

Covid-19 hospitalizations in the US reached a record 100,000 on Wednesday, straining health-care systems in numerous states. Hospitalisations have set new records almost daily since November 10 in the nation's largest and longest surge.

Covid-19 hospitalizations in the US reached a record 100,000 on Wednesday, straining health-care systems in numerous states. Hospitalisations have set new records almost daily since November 10 in the nation's largest and longest surge. Also read | Vaccines insufficient to prevent surge in coronavirus for next six months: WHO According to the health experts, the number will continue to climb, as Thanksgiving gatherings and holidays are expected to accelerate an already rampant spread of the virus this fall. "There are 100,226 people currently hospitalized with COVID-19 in the US — the first time hospitalizations have exceeded 100k," the COVID Tracking Project said in a tweet. The current number of hospitalized patients underscores the scope and severity of the current phase of the U.S. outbreak. Never before had the number of hospitalized Covid patients surpassed 60,000, according to data compiled by the Covid Tracking Project, which is run by journalists at The Atlantic. Meanwhile, US officials have said that they expect to have enough vaccine doses to immunize about 100 million higher-risk people by the end of February. But the World Health Organization does not believe there will be enough quantities of coronavirus vaccines in the next three to six months to prevent a surge of infections, its top emergency expert said. "We are not going to have sufficient vaccinations in place to prevent a surge in cases for three to six months," Mike Ryan told a social media event, calling on people to maintain social distancing and respect other measures to restrict the spread of COVID-19. The World Health Organization (WHO) has identified 49 "candidate vaccines" at the stage of clinical trials in humans by mid-November, up from 11 in mid-June. WHO had received data from Pfizer and BioNTech on the COVID-19 vaccine and was reviewing it for "possible listing for emergency use", a benchmark for countries to authorise national use. (With inputs from agencies)

United States Covid-19 hospitalisations top 100,000, hospitals stretched beyond limit

The Indian Navy was ready to face dual challenges from COVID-19 and China, stating that they are determined to remain stable during these test times, Navy Chief Admiral Karambir Singh said on Thursday.

Indian Navy chief says, "Alive to any threat in maritime domain, P8i aircraft deployed"

After pausing production of 'Real Housewives of Beverly Hills' recently, it has come to light that there's been a severe COVID-19 outbreak among the cast and crew of the show.

According to TMZ, Kyle Richards, Kathy Hilton and Dorit Kemsley have all tested positive for COVID-19. The positive tests come just a week after production was shut down due to a crew member's positive test.

The report claims that none of the three women has "serious symptoms" and all are recovering at home. It's believed that they are nearing the end of their COVID-19 battles.

Sources quickly added that the women contracted the virus from hanging out together and not from filming. 
 
'RHOBH'&nbsp;filming began filming its newest season five weeks ago. At the time of the production halt, none of the Season 11 `Housewives` - including Kyle Richards, Lisa Rinna, Erika Girardi, Dorit Kemsley, Garcelle Beauvais, or Crystal Kung Minkoff - have spoken out about the situation. 
 
However, the 51-year-old star Richards shared on her Instagram Stories on Thursday that she was "not feeling well." She did not reveal whether she tested positive. Earlier, the LA County Department of Health reported the highest number of new COVID-19 cases with 6,124. In mid-November, Page Six reported that filming was shut down on 'The Real Housewives of Altanta'&nbsp;when a production member tested positive for COVID-19.&nbsp;

After pausing production of 'Real Housewives of Beverly Hills' recently, it has come to light that there's been a severe COVID-19 outbreak among the cast and crew of the show.

After pausing production of 'Real Housewives of Beverly Hills' recently, it has come to light that there's been a severe COVID-19 outbreak among the cast and crew of the show. According to TMZ, Kyle Richards, Kathy Hilton and Dorit Kemsley have all tested positive for COVID-19. The positive tests come just a week after production was shut down due to a crew member's positive test. The report claims that none of the three women has "serious symptoms" and all are recovering at home. It's believed that they are nearing the end of their COVID-19 battles. Sources quickly added that the women contracted the virus from hanging out together and not from filming. 'RHOBH' filming began filming its newest season five weeks ago. At the time of the production halt, none of the Season 11 `Housewives` - including Kyle Richards, Lisa Rinna, Erika Girardi, Dorit Kemsley, Garcelle Beauvais, or Crystal Kung Minkoff - have spoken out about the situation. However, the 51-year-old star Richards shared on her Instagram Stories on Thursday that she was "not feeling well." She did not reveal whether she tested positive. Earlier, the LA County Department of Health reported the highest number of new COVID-19 cases with 6,124. In mid-November, Page Six reported that filming was shut down on 'The Real Housewives of Altanta' when a production member tested positive for COVID-19.

'Real Housewives of Beverly Hills' cast tests positive for COVID-19: Report

The federal government is distributing the vaccines based on a state’s population. Cuomo said an estimated 40,000 more doses of Moderna’s vaccine are expected by the end of the month

1st batch of 170,000 doses to arrive in New York by Dec 15

The US Centres for Disease Control and Prevention (CDC) will shorten the recommended length of quarantine after exposure to someone who is positive for COVID-19, the Associated Press reported on Tuesday.

The updated guidelines will let people who have come in contact to someone infected with the coronavirus to end quarantine after 10 days, or seven days provided they receive a negative test result, the report said.

That's down from the 14-day period recommended since the onset of the pandemic.

The policy change has been discussed for some time, as scientists have studied the incubation period for the virus. It was discussed Tuesday at a White House coronavirus task force meeting.

The US Centres for Disease Control and Prevention (CDC) will shorten the recommended length of quarantine after exposure to someone who is positive for COVID-19, the Associated Press reported on Tuesday.

The US Centres for Disease Control and Prevention (CDC) will shorten the recommended length of quarantine after exposure to someone who is positive for COVID-19, the Associated Press reported on Tuesday. The updated guidelines will let people who have come in contact to someone infected with the coronavirus to end quarantine after 10 days, or seven days provided they receive a negative test result, the report said. That's down from the 14-day period recommended since the onset of the pandemic. The policy change has been discussed for some time, as scientists have studied the incubation period for the virus. It was discussed Tuesday at a White House coronavirus task force meeting.

US CDC to shorten COVID-19 quarantine to 10 days

A Brooklyn trial was postponed after the defense lawyers said they were unwilling to spend weeks in a cramped courtroom. In Manhattan, a woman summoned for jury duty told the court she had been sick with the coronavirus and was symptomatic. Another trial, in the Bronx, was canceled when four courthouse staff members tested positive.

Since October, state and federal court officials have taken extraordinary measures to restart criminal trials in New York City. They have constructed Plexiglas boxes with special air filters in court. They have asked witnesses to testify in face shields and have spread jurors out in courtroom galleries.

But those efforts have not stopped the virus from disrupting nearly every step of the process. The state and federal courts in the city have been able to complete only nine criminal jury trials since the pandemic hit in March, officials said. Last year, there were about 800 criminal trials in the city.

For months, the logistical problems have threatened the ability of hundreds of defendants to secure their constitutional right to a speedy trial. Now, as a second wave of the virus threatens the region, the delays are worsening — and officials foresee the backlog of unresolved cases continuing to grow.

Last month, the chief judge in New York state halted new jury trials until further notice because of surging virus cases. More than 400 defendants have been waiting in New York City jails for more than two years for their cases to be resolved, according to the mayor’s office.

“Is it fair for people to be languishing in pretrial detention and presumed innocent with no prospect of a trial in the future for them?” said New York’s chief administrative judge, Lawrence K. Marks. “A criminal justice system cannot be, in any sense of the word, fully functioning, if it is not conducting jury trials.”

And in the last week, the federal courts in the city also announced that all trials would be suspended until mid-January.

Some prosecutors, citing safety concerns, have pushed to delay trials because their witnesses live out of state or work in hospitals with COVID-19 patients. In other cases, prosecutors said the fears of catching the virus during trials had been overblown.

The problems in New York have been mirrored across the country. Federal judges in Nebraska, Nevada, Colorado and several other jurisdictions recently suspended jury trials in response to rising virus cases. A court in McKinney, Texas, a suburb of Dallas, held the state’s first virtual criminal trial last month.

Each court has determined its own protocols. One local courthouse in Orange County, California, has completed 114 criminal trials since May, while the federal courthouse across the street has determined it is unsafe to hold any trials.

In New York City courts, the challenge of preventing the virus’s spread is magnified by the dense population. In normal times, clerks, court officers and lawyers squeeze into courtroom galleries and line the crowded hallways, waiting for cases to be called.

In November, at least three dozen people who appeared in nine criminal courthouses in the city tested positive for the virus, according to the state’s court administrators.

Many judges have been eager to begin trials, worried about violating the constitutional rights of people charged with crimes. Without speedy trials, jails become overcrowded, evidence grows stale, and witnesses’ memories fade.

Early in the pandemic, after New York City officials released hundreds of inmates, the city’s jail population dropped to its lowest level since the 1940s. But the population has increased again — to 4,669 people last month — raising fears about the virus spreading among inmates and jail staff. Most of the inmates are awaiting trial, according to the Center for Court Innovation, a criminal justice nonprofit.

But one of the biggest hurdles to restarting trials has been finding defense lawyers who are willing to do them.

At a federal hearing in Manhattan, Susan Kellman, a defense lawyer, said she felt unsafe visiting her client in jail, which hindered their ability to prepare for a drug-trafficking trial that had been scheduled for October. Her client has been adamant about going to trial quickly, she said, and regularly screams at her on the telephone.

“I’m a single parent. I have two kids. I’m really not ready to die,” she told the judge, who rescheduled the trial.

In Brooklyn, Alexander Zhukov, a defendant charged in a cybercrime scheme, was finally set to begin trial last month after waiting in jail for two years. But all three of his lawyers asked to quit weeks before the start date, citing fears about the new virus wave.

Saritha Komatireddy, a prosecutor on the case, questioned why the lawyers had raised the concern for the first time so close to trial.

“They may be entitled to their own fears, but they’re not entitled to their own facts,” she said at a recent hearing. “Trials are possible.”

Out of desperation, Zhukov asked the judge if he could represent himself, even though Zhukov, a Russian national, has never studied American law.

“For me, there is no options any more,” Zhukov said at the hearing. “It’s a must choice right now. It’s the only opportunity to get to trial on time. Otherwise, it will be postponed, postponed, postponed, postponed.”

The judge assigned Zhukov a new lawyer and delayed the trial until at least February.

Courthouse security officers and defense lawyers have sued to oppose the reopening of New York’s state courts, accusing court administrators of failing to take adequate safety measures.

The chief administrative judge has said the courts are thoroughly and regularly cleaned. But a team of physicians hired by the city’s public defender groups contended in an August report that the state’s courthouses were ill-equipped to stop the spread of a virus, pointing to crowded holding cells for defendants, improperly installed plexiglass and poorly ventilated rooms.

The virus has infiltrated the city’s courtrooms in ways that threaten the health of those inside and the constitutional rights of defendants.

At a drug trial in state court in Manhattan in October, a police officer testified while wearing a see-through mask and face shield, surrounded by Plexiglas. But his testimony was interrupted by drilling noises from the sidewalk, which were audible because the courtroom’s windows had been propped open to improve ventilation.

The jurors and the defendant, Demetre Cornish, strained to hear the officer. The judge decided to close a window, but kept the others open, saying, “We want to keep the air circulating.”

Cornish was acquitted by the jury of some drug and firearm offenses but convicted of others. His lawyer, Thomas Kenniff, filed a motion Monday asking the judge to set aside the verdict, arguing that his client did not have a fair and public trial because of restrictions caused by the pandemic.

Cornish’s relatives were denied entry into the courtroom. Their presence would have “had the potential to allow jurors to see him as an individual as opposed to an anonymous masked Black man sitting in the defendant’s chair,” Kenniff wrote.

Face coverings prevented the defense from assessing facial expressions and reactions of potential jurors, Kenniff said.

And the 12-person jury had included only two Black jurors and did not reflect the demographics of the borough, Kenniff said. Some defense lawyers have raised concerns that the virus’s disproportionate effect on Black and Latino residents might make jury pools less representative.

Even before trials were halted entirely, jury selection had been transformed during the pandemic, screening out anyone uncomfortable with health risks. Once seated, juries deliberated in a separate courtroom, giving them more space than they had in cramped jury rooms.

Still, some jurors have not seemed keen to stay for too long. A murder trial in the Bronx in July ended in an acquittal on all charges after jurors deliberated for less than an hour. A federal gun possession trial in Brooklyn last month led to a guilty verdict in 30 minutes.

Communication between lawyers and their clients, who are supposed to sit 6 feet apart during trial, has been difficult. Federal courts have provided special phones that operate like walkie-talkies, although lawyers have said that the whispered conversations are picked up by microphones used to address the court.

“The whole technology seems like it was from the days of Alexander Graham Bell,” said Eric Creizman, a lawyer whose client was convicted of securities fraud last month after a federal trial in Manhattan.

Even with careful preparations, trials have been derailed by the pandemic.

On Long Island, a judge stopped a trial after two days of testimony in September when the defendant revealed that his wife had tested positive for the virus. He said he was unable to isolate from her inside their small house. The trial resumed last month, and a jury convicted him on several drug offenses.

One or two other trials that had been halted in March may have also resumed during the pandemic, state court officials said.

“We are concerned for both victims and defendants that the wheels of justice continue to move,” said Karen Friedman Agnifilo, chief assistant to the Manhattan district attorney. “Languishing court cases is not good for anybody.”

A Brooklyn trial was postponed after the defense lawyers said they were unwilling to spend weeks in a cramped courtroom. In Manhattan, a woman summoned for jury duty told the court she had been sick with the coronavirus and was symptomatic.

A Brooklyn trial was postponed after the defense lawyers said they were unwilling to spend weeks in a cramped courtroom. In Manhattan, a woman summoned for jury duty told the court she had been sick with the coronavirus and was symptomatic. Another trial, in the Bronx, was canceled when four courthouse staff members tested positive. Since October, state and federal court officials have taken extraordinary measures to restart criminal trials in New York City. They have constructed Plexiglas boxes with special air filters in court. They have asked witnesses to testify in face shields and have spread jurors out in courtroom galleries. But those efforts have not stopped the virus from disrupting nearly every step of the process. The state and federal courts in the city have been able to complete only nine criminal jury trials since the pandemic hit in March, officials said. Last year, there were about 800 criminal trials in the city. For months, the logistical problems have threatened the ability of hundreds of defendants to secure their constitutional right to a speedy trial. Now, as a second wave of the virus threatens the region, the delays are worsening — and officials foresee the backlog of unresolved cases continuing to grow. Last month, the chief judge in New York state halted new jury trials until further notice because of surging virus cases. More than 400 defendants have been waiting in New York City jails for more than two years for their cases to be resolved, according to the mayor’s office. “Is it fair for people to be languishing in pretrial detention and presumed innocent with no prospect of a trial in the future for them?” said New York’s chief administrative judge, Lawrence K. Marks. “A criminal justice system cannot be, in any sense of the word, fully functioning, if it is not conducting jury trials.” And in the last week, the federal courts in the city also announced that all trials would be suspended until mid-January. Some prosecutors, citing safety concerns, have pushed to delay trials because their witnesses live out of state or work in hospitals with COVID-19 patients. In other cases, prosecutors said the fears of catching the virus during trials had been overblown. The problems in New York have been mirrored across the country. Federal judges in Nebraska, Nevada, Colorado and several other jurisdictions recently suspended jury trials in response to rising virus cases. A court in McKinney, Texas, a suburb of Dallas, held the state’s first virtual criminal trial last month. Each court has determined its own protocols. One local courthouse in Orange County, California, has completed 114 criminal trials since May, while the federal courthouse across the street has determined it is unsafe to hold any trials. In New York City courts, the challenge of preventing the virus’s spread is magnified by the dense population. In normal times, clerks, court officers and lawyers squeeze into courtroom galleries and line the crowded hallways, waiting for cases to be called. In November, at least three dozen people who appeared in nine criminal courthouses in the city tested positive for the virus, according to the state’s court administrators. Many judges have been eager to begin trials, worried about violating the constitutional rights of people charged with crimes. Without speedy trials, jails become overcrowded, evidence grows stale, and witnesses’ memories fade. Early in the pandemic, after New York City officials released hundreds of inmates, the city’s jail population dropped to its lowest level since the 1940s. But the population has increased again — to 4,669 people last month — raising fears about the virus spreading among inmates and jail staff. Most of the inmates are awaiting trial, according to the Center for Court Innovation, a criminal justice nonprofit. But one of the biggest hurdles to restarting trials has been finding defense lawyers who are willing to do them. At a federal hearing in Manhattan, Susan Kellman, a defense lawyer, said she felt unsafe visiting her client in jail, which hindered their ability to prepare for a drug-trafficking trial that had been scheduled for October. Her client has been adamant about going to trial quickly, she said, and regularly screams at her on the telephone. “I’m a single parent. I have two kids. I’m really not ready to die,” she told the judge, who rescheduled the trial. In Brooklyn, Alexander Zhukov, a defendant charged in a cybercrime scheme, was finally set to begin trial last month after waiting in jail for two years. But all three of his lawyers asked to quit weeks before the start date, citing fears about the new virus wave. Saritha Komatireddy, a prosecutor on the case, questioned why the lawyers had raised the concern for the first time so close to trial. “They may be entitled to their own fears, but they’re not entitled to their own facts,” she said at a recent hearing. “Trials are possible.” Out of desperation, Zhukov asked the judge if he could represent himself, even though Zhukov, a Russian national, has never studied American law. “For me, there is no options any more,” Zhukov said at the hearing. “It’s a must choice right now. It’s the only opportunity to get to trial on time. Otherwise, it will be postponed, postponed, postponed, postponed.” The judge assigned Zhukov a new lawyer and delayed the trial until at least February. Courthouse security officers and defense lawyers have sued to oppose the reopening of New York’s state courts, accusing court administrators of failing to take adequate safety measures. The chief administrative judge has said the courts are thoroughly and regularly cleaned. But a team of physicians hired by the city’s public defender groups contended in an August report that the state’s courthouses were ill-equipped to stop the spread of a virus, pointing to crowded holding cells for defendants, improperly installed plexiglass and poorly ventilated rooms. The virus has infiltrated the city’s courtrooms in ways that threaten the health of those inside and the constitutional rights of defendants. At a drug trial in state court in Manhattan in October, a police officer testified while wearing a see-through mask and face shield, surrounded by Plexiglas. But his testimony was interrupted by drilling noises from the sidewalk, which were audible because the courtroom’s windows had been propped open to improve ventilation. The jurors and the defendant, Demetre Cornish, strained to hear the officer. The judge decided to close a window, but kept the others open, saying, “We want to keep the air circulating.” Cornish was acquitted by the jury of some drug and firearm offenses but convicted of others. His lawyer, Thomas Kenniff, filed a motion Monday asking the judge to set aside the verdict, arguing that his client did not have a fair and public trial because of restrictions caused by the pandemic. Cornish’s relatives were denied entry into the courtroom. Their presence would have “had the potential to allow jurors to see him as an individual as opposed to an anonymous masked Black man sitting in the defendant’s chair,” Kenniff wrote. Face coverings prevented the defense from assessing facial expressions and reactions of potential jurors, Kenniff said. And the 12-person jury had included only two Black jurors and did not reflect the demographics of the borough, Kenniff said. Some defense lawyers have raised concerns that the virus’s disproportionate effect on Black and Latino residents might make jury pools less representative. Even before trials were halted entirely, jury selection had been transformed during the pandemic, screening out anyone uncomfortable with health risks. Once seated, juries deliberated in a separate courtroom, giving them more space than they had in cramped jury rooms. Still, some jurors have not seemed keen to stay for too long. A murder trial in the Bronx in July ended in an acquittal on all charges after jurors deliberated for less than an hour. A federal gun possession trial in Brooklyn last month led to a guilty verdict in 30 minutes. Communication between lawyers and their clients, who are supposed to sit 6 feet apart during trial, has been difficult. Federal courts have provided special phones that operate like walkie-talkies, although lawyers have said that the whispered conversations are picked up by microphones used to address the court. “The whole technology seems like it was from the days of Alexander Graham Bell,” said Eric Creizman, a lawyer whose client was convicted of securities fraud last month after a federal trial in Manhattan. Even with careful preparations, trials have been derailed by the pandemic. On Long Island, a judge stopped a trial after two days of testimony in September when the defendant revealed that his wife had tested positive for the virus. He said he was unable to isolate from her inside their small house. The trial resumed last month, and a jury convicted him on several drug offenses. One or two other trials that had been halted in March may have also resumed during the pandemic, state court officials said. “We are concerned for both victims and defendants that the wheels of justice continue to move,” said Karen Friedman Agnifilo, chief assistant to the Manhattan district attorney. “Languishing court cases is not good for anybody.”

Only 9 trials in 9 months: Virus wreaks havoc on NYC courts

<article>
For the last 20 years, whenever patients asked me about exercising while recovering from a viral illness like the flu, I gave the same advice: Listen to your body. If exercise usually makes you feel better, go for it.

COVID-19 has changed my advice.

Early in the pandemic, as the initial wave of patients with COVID-19 began to recover and clinically improve, my colleagues and I noticed that some of our patients were struggling to return to their previous activity levels. Some cited extreme fatigue and breathing difficulties, while others felt as if they just could not get back to their normal fitness output. We also began to hear of a higher than normal incidence of cardiac arrhythmias from myocarditis, inflammation of the heart muscle that can weaken the heart and, in rare cases, cause sudden cardiac arrest. Other complications like blood clots were also cropping up.

What was surprising is that we saw these problems in previously healthy and fit patients who had only mild illness and never required hospitalization for COVID-19.

In my sports medicine practice, a cyclist in her 40s with recent COVID-19 symptoms had leg pain that was abnormal enough to warrant an ultrasound, which showed near complete cessation of blood flow because of arterial and venous blood clots in both legs. Thankfully, our team caught these early enough that they did not spread to her lungs, which ultimately could have killed her. Recently, a college student in Indiana with COVID-19 died from a blood clot that traveled to her lungs. As the pandemic has evolved, we have learned of a much higher risk of blood clots from people who contract the virus.

In those early months of the pandemic, my colleagues and I learned of a New York City mental health worker in her early 30s, a dedicated athlete with no underlying health problems, who developed symptoms of COVID-19. Her low-grade fever and congestion went away, but she continued to feel “sluggish.” As she had done many other times after getting over an illness, she went for a run to feel better. She died on the run, of cardiac arrest; it appears she had undiagnosed myocarditis caused by COVID-19.

We now know the heart is a particular cause for concern after coronavirus infection. A study in JAMA Cardiology looked at 100 men and women in Germany, average age 49, who had recovered from COVID-19 and found signs of myocarditis in 78%. Most had been healthy, with no preexisting medical conditions. A smaller study of college athletes who had recovered from COVID-19 found that 15% had signs of heart inflammation.

As the pandemic continues, we have heard countless stories of elite athletes in top physical condition struggling to regain their form after COVID-19. More than a dozen women on the U.S. Olympic rowing team who contracted the virus in March described persistent fatigue for weeks after the initial illness. Recreational athletes, including runners and triathletes, have complained of prolonged respiratory symptoms during exercise. Pulmonary issues from COVID-19, including pneumonia, have caused breathing difficulty during exercise for weeks or months following infection.

To help patients safely return to activity after mild to moderate COVID-19 infection, my colleagues at Hospital for Special Surgery and I published an evidence-based set of guidelines based on the existing medical literature and our evolving understanding of the disease. Our “return to activity” guidelines urge far more caution than in the past, based on the unpredictable nature of how the virus affects each person.

Anyone who had severe illness or was hospitalized with COVID-19 needs to consult a physician about whether it is safe to exercise. But even people who experienced mild illness or no symptoms need to take precautions before exercising again. Among our new recommendations:

Do not exercise if you are still sick.&nbsp;Do not exercise if you have active symptoms, including a fever, cough, chest pain, shortness of breath at rest or palpitations.

Slowly return to exercise.&nbsp;Even if you had only mild symptoms, with no chest pain or shortness of breath, you should still wait until you have at least seven days with no symptoms before returning to exercise. Start at just 50% of normal intensity. A gradual, step-by-step and slow return to full activity is recommended.

Stop exercise if symptoms return.&nbsp;If you develop symptoms after exercising, including chest pain, fever, palpitations or shortness of breath, see a doctor.

See a cardiologist before exercising.&nbsp;If you experienced chest pain, shortness of breath or fatigue during your illness, you should see a cardiologist before restarting sports activity. Depending on how you feel, your doctor may conduct a test for myocardial inflammation.

Get tested.&nbsp;If you have cold or flu symptoms, get tested for COVID-19 before you return to exercise. If you think you might have had COVID-19, a test might help you and your doctor make decisions about safely returning to exercise.

And remember, as doctors we can run tests, but&nbsp;you&nbsp;know your own body better than anyone else. You know how you normally feel when you walk up the stairs, when you run, when you bike. If you have had COVID-19, are those things harder for you? Are you noticing a change in your body? If the answer is “yes,” it is important to speak with your doctor.

Even if you have never been diagnosed with COVID-19, be mindful of how you are feeling. Many people with COVID-19 do not know they have it, or have general symptoms like gastrointestinal upset, fatigue or muscle aches. So if you have been feeling “off” during exercise, listen to your body, ease up and check with your doctor.

COVID-19, an aggressive virus, spreads easily and carries significant morbidity and mortality. Cardiac risk in particular is greater with COVID-19 than with other viral diseases, so it makes sense to use caution.
</article>

For the last 20 years, whenever patients asked me about exercising while recovering from a viral illness like the flu, I gave the same advice: Listen to your body.

For the last 20 years, whenever patients asked me about exercising while recovering from a viral illness like the flu, I gave the same advice: Listen to your body. If exercise usually makes you feel better, go for it. COVID-19 has changed my advice. Early in the pandemic, as the initial wave of patients with COVID-19 began to recover and clinically improve, my colleagues and I noticed that some of our patients were struggling to return to their previous activity levels. Some cited extreme fatigue and breathing difficulties, while others felt as if they just could not get back to their normal fitness output. We also began to hear of a higher than normal incidence of cardiac arrhythmias from myocarditis, inflammation of the heart muscle that can weaken the heart and, in rare cases, cause sudden cardiac arrest. Other complications like blood clots were also cropping up. What was surprising is that we saw these problems in previously healthy and fit patients who had only mild illness and never required hospitalization for COVID-19. In my sports medicine practice, a cyclist in her 40s with recent COVID-19 symptoms had leg pain that was abnormal enough to warrant an ultrasound, which showed near complete cessation of blood flow because of arterial and venous blood clots in both legs. Thankfully, our team caught these early enough that they did not spread to her lungs, which ultimately could have killed her. Recently, a college student in Indiana with COVID-19 died from a blood clot that traveled to her lungs. As the pandemic has evolved, we have learned of a much higher risk of blood clots from people who contract the virus. In those early months of the pandemic, my colleagues and I learned of a New York City mental health worker in her early 30s, a dedicated athlete with no underlying health problems, who developed symptoms of COVID-19. Her low-grade fever and congestion went away, but she continued to feel “sluggish.” As she had done many other times after getting over an illness, she went for a run to feel better. She died on the run, of cardiac arrest; it appears she had undiagnosed myocarditis caused by COVID-19. We now know the heart is a particular cause for concern after coronavirus infection. A study in JAMA Cardiology looked at 100 men and women in Germany, average age 49, who had recovered from COVID-19 and found signs of myocarditis in 78%. Most had been healthy, with no preexisting medical conditions. A smaller study of college athletes who had recovered from COVID-19 found that 15% had signs of heart inflammation. As the pandemic continues, we have heard countless stories of elite athletes in top physical condition struggling to regain their form after COVID-19. More than a dozen women on the U.S. Olympic rowing team who contracted the virus in March described persistent fatigue for weeks after the initial illness. Recreational athletes, including runners and triathletes, have complained of prolonged respiratory symptoms during exercise. Pulmonary issues from COVID-19, including pneumonia, have caused breathing difficulty during exercise for weeks or months following infection. To help patients safely return to activity after mild to moderate COVID-19 infection, my colleagues at Hospital for Special Surgery and I published an evidence-based set of guidelines based on the existing medical literature and our evolving understanding of the disease. Our “return to activity” guidelines urge far more caution than in the past, based on the unpredictable nature of how the virus affects each person. Anyone who had severe illness or was hospitalized with COVID-19 needs to consult a physician about whether it is safe to exercise. But even people who experienced mild illness or no symptoms need to take precautions before exercising again. Among our new recommendations: Do not exercise if you are still sick. Do not exercise if you have active symptoms, including a fever, cough, chest pain, shortness of breath at rest or palpitations. Slowly return to exercise. Even if you had only mild symptoms, with no chest pain or shortness of breath, you should still wait until you have at least seven days with no symptoms before returning to exercise. Start at just 50% of normal intensity. A gradual, step-by-step and slow return to full activity is recommended. Stop exercise if symptoms return. If you develop symptoms after exercising, including chest pain, fever, palpitations or shortness of breath, see a doctor. See a cardiologist before exercising. If you experienced chest pain, shortness of breath or fatigue during your illness, you should see a cardiologist before restarting sports activity. Depending on how you feel, your doctor may conduct a test for myocardial inflammation. Get tested. If you have cold or flu symptoms, get tested for COVID-19 before you return to exercise. If you think you might have had COVID-19, a test might help you and your doctor make decisions about safely returning to exercise. And remember, as doctors we can run tests, but you know your own body better than anyone else. You know how you normally feel when you walk up the stairs, when you run, when you bike. If you have had COVID-19, are those things harder for you? Are you noticing a change in your body? If the answer is “yes,” it is important to speak with your doctor. Even if you have never been diagnosed with COVID-19, be mindful of how you are feeling. Many people with COVID-19 do not know they have it, or have general symptoms like gastrointestinal upset, fatigue or muscle aches. So if you have been feeling “off” during exercise, listen to your body, ease up and check with your doctor. COVID-19, an aggressive virus, spreads easily and carries significant morbidity and mortality. Cardiac risk in particular is greater with COVID-19 than with other viral diseases, so it makes sense to use caution.

Exercise after COVID-19? Take it slow.

Several foreign envoys will be visiting Hyderabad on&nbsp;December 9 to see India's covid vaccine development programme. The visit, organised by India's Ministry of External Affairs is expected to be a one day visit.

India is expected to be a major centre&nbsp;of the global covid vaccine manufacturing and supply. Amidst the COVID pandemic, India has emerged as the Pharma Capital of the world supplying medicines such as HCQ, Paracetamol to more than 150 countries.

The visit was one of the key outcomes of foreign secretary Harsh Shringla's meet with the envoy earlier this month in Delhi. On 6th November, India's FS along with Principal Scientific Advisor to the Government of India, Prof. K. Vijay Raghavan, Health Secretary Rajesh Bhushan, Secretary, Department of Biotechnology, Dr. Renu Swarup, Secretary, Department of Science &amp; Technology, &nbsp;Ashutosh Sharma briefed More than 190 heads of diplomatic missions on India's action on COVID pandemic.

On vaccine development programme, New Delhi has organised training programmes on clinical trials for neighbouring countries in which nearly 90 experts from 8 countries participated. &nbsp;It has sent aid, in terms of food and medicines to 5 Indian ocean countries--Maldives, Mauritius, Madagascar, Comoros and Seychelles and 4 African countries--Sudan, South Sudan, Djibouti and Eritrea.

Several foreign envoys will be visiting Hyderabad on December 9 to see India's covid vaccine development programme. The visit, organised by India's Ministry of External Affairs is expected to be a one day visit.

Several foreign envoys will be visiting Hyderabad on December 9 to see India's covid vaccine development programme. The visit, organised by India's Ministry of External Affairs is expected to be a one day visit. India is expected to be a major centre of the global covid vaccine manufacturing and supply. Amidst the COVID pandemic, India has emerged as the Pharma Capital of the world supplying medicines such as HCQ, Paracetamol to more than 150 countries. The visit was one of the key outcomes of foreign secretary Harsh Shringla's meet with the envoy earlier this month in Delhi. On 6th November, India's FS along with Principal Scientific Advisor to the Government of India, Prof. K. Vijay Raghavan, Health Secretary Rajesh Bhushan, Secretary, Department of Biotechnology, Dr. Renu Swarup, Secretary, Department of Science & Technology, Ashutosh Sharma briefed More than 190 heads of diplomatic missions on India's action on COVID pandemic. On vaccine development programme, New Delhi has organised training programmes on clinical trials for neighbouring countries in which nearly 90 experts from 8 countries participated. It has sent aid, in terms of food and medicines to 5 Indian ocean countries--Maldives, Mauritius, Madagascar, Comoros and Seychelles and 4 African countries--Sudan, South Sudan, Djibouti and Eritrea.

Foreign envoys to visit Hyderabad on Dec 9 to see India's covid vaccine programme

After the United Kingdom approved an emergency authorisation request for the general use of COVID-19 vaccine developed by Pfizer and BioNTech, the drug regulator of the European Union claimed that a longer process to ascertain the safety of vaccines is required.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/uk-approves-pfizer-biontech-vaccine-for-use-first-in-the-world-346882/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

It added that their approval process, which takes longer, is safer than the emergency use authorisation route taken by the UK. The European Medicines Agency said - “EMA considers that the conditional marketing authorisation is the most appropriate regulatory mechanism for use in the current pandemic emergency."&nbsp;

It added that conditional authorisation leaves room for more evidence based roll out, and leaves space for more checks of the safety imbued in the vaccines, as opposed to the emergency process chosen by Britain.

Also read:&nbsp;<a href="http://13.235.153.162/world/uk-becomes-first-country-to-approve-pfizer-biontech-covid-vaccine-for-general-use-346858" hreflang="en">UK becomes first country to approve Pfizer-BioNTech Covid vaccine for general use</a>

On Tuesday, the EMA had said that it will decide whether to authorise Pfizer’s vaccine or not by December 29 after taking into account safety and feasibility.

On Wednesday, Britain became the world’s first to approve Pfizer-BioNTech’s vaccine for COVID-19, which is set to be rolled out starting next week.

"The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech's Covid-19 vaccine for use," the British department of health said in a statement.

Also read:&nbsp;<a href="http://13.235.153.162/world/in-europe-before-the-end-of-2020-pfizer-biontech-files-for-eu-approval-of-coronavirus-vaccine-346707" hreflang="en">'In Europe before the end of 2020': Pfizer-BioNTech files for EU approval of coronavirus vaccine</a>

"The vaccine will be made available across the UK from next week," the statement added.

People working in care home residents, along with health care workers and residents will be prioritised for the shot. Responding to the approval, Pfizer announced that Britain’s authorisation for emergency use is historic in the fight against coronavirus.

After the United Kingdom approved an emergency authorisation request for the general use of COVID-19 vaccine developed by Pfizer and BioNTech, the drug regulator of the European Union claimed that a longer process to ascertain the safety of vaccines is required.

After the United Kingdom approved an emergency authorisation request for the general use of COVID-19 vaccine developed by Pfizer and BioNTech, the drug regulator of the European Union claimed that a longer process to ascertain the safety of vaccines is required. It added that their approval process, which takes longer, is safer than the emergency use authorisation route taken by the UK. The European Medicines Agency said - “EMA considers that the conditional marketing authorisation is the most appropriate regulatory mechanism for use in the current pandemic emergency." It added that conditional authorisation leaves room for more evidence based roll out, and leaves space for more checks of the safety imbued in the vaccines, as opposed to the emergency process chosen by Britain. Also read: UK becomes first country to approve Pfizer-BioNTech Covid vaccine for general use On Tuesday, the EMA had said that it will decide whether to authorise Pfizer’s vaccine or not by December 29 after taking into account safety and feasibility. On Wednesday, Britain became the world’s first to approve Pfizer-BioNTech’s vaccine for COVID-19, which is set to be rolled out starting next week. "The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech's Covid-19 vaccine for use," the British department of health said in a statement. Also read: 'In Europe before the end of 2020': Pfizer-BioNTech files for EU approval of coronavirus vaccine "The vaccine will be made available across the UK from next week," the statement added. People working in care home residents, along with health care workers and residents will be prioritised for the shot. Responding to the approval, Pfizer announced that Britain’s authorisation for emergency use is historic in the fight against coronavirus.

After UK approves Pfizer's COVID-19 vaccine, EU warns against rushed authorisation

The US company is submitting the data to the regulators in the US, Europe and the UK for an emergency licence.

A turning point in the COVID-19 Pandemic as Moderna claims 100% efficacy in severe cases

India reported 31,118 new COVID-19 infections in the last 24 hours, according to the Union Ministry of Health and Family Welfare`s data on Tuesday.

The overall coronavirus cases reached 94,62,810 including 4,35,603 active cases and 88,89,585 recoveries. With 482 new deaths, the cumulative toll mounted to 1,37,621.

A total 12,78,727 cases were reported in November, a decrease from October's 18,71,498, accounting for about 13.51 per cent of the total instances of the viral infection reported in the country so far.

The past month also saw 15,510 lives lost due to the disease, which is just around 11.27 per cent of the total 1,37,621 deaths recorded so far.

The number of people who have recuperated from the disease surged to 88,89,585, pushing the national recovery rate to 93.94 per cent.

The COVID-19 case fatality rate stands at 1.45 per cent. The active COVID-19 caseload remained below five lakh for the 21st consecutive day.

There are 4,35,603 active cases in the country which comprise 4.60 per cent of the total caseload, the data stated.

India's COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and 40 lakh on September 5.

It went past 50 lakh on September 16, &nbsp;60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, and surpassed 90 lakh on November 20.

According to the ICMR, 14,13, 49,298 samples have been tested so far with 9,69,332 samples being tested on Monday.

The 482 new fatalities include 108 from Delhi, 80 from Maharashtra, 48 from West Bengal, 27 each from Haryana and Punjab, 21 each from Chhattisgarh and Kerala and 20 each from Gujarat and Rajasthan.

Total 1,37,621 deaths reported so far in the country include 47,151 from Maharashtra followed by 11,778 from Karnataka, 11,712 from Tamil Nadu, 9,174 from Delhi, 8,424 from West Bengal, 7,761 from Uttar Pradesh, 6,992 from Andhra Pradesh, 4,807 from Punjab, 3,989 from Gujarat and 3,260 from Madhya Pradesh.

The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.

"Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation.

(With inputs from agencies)

India reported 31,118 new COVID-19 infections in the last 24 hours, according to the Union Ministry of Health and Family Welfare`s data on Tuesday. The overall coronavirus cases reached 94,62,810 including 4,35,603 active cases and 88,89,585 recoveries.

India reported 31,118 new COVID-19 infections in the last 24 hours, according to the Union Ministry of Health and Family Welfare`s data on Tuesday. The overall coronavirus cases reached 94,62,810 including 4,35,603 active cases and 88,89,585 recoveries. With 482 new deaths, the cumulative toll mounted to 1,37,621. A total 12,78,727 cases were reported in November, a decrease from October's 18,71,498, accounting for about 13.51 per cent of the total instances of the viral infection reported in the country so far. The past month also saw 15,510 lives lost due to the disease, which is just around 11.27 per cent of the total 1,37,621 deaths recorded so far. The number of people who have recuperated from the disease surged to 88,89,585, pushing the national recovery rate to 93.94 per cent. The COVID-19 case fatality rate stands at 1.45 per cent. The active COVID-19 caseload remained below five lakh for the 21st consecutive day. There are 4,35,603 active cases in the country which comprise 4.60 per cent of the total caseload, the data stated. India's COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and 40 lakh on September 5. It went past 50 lakh on September 16, 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, and surpassed 90 lakh on November 20. According to the ICMR, 14,13, 49,298 samples have been tested so far with 9,69,332 samples being tested on Monday. The 482 new fatalities include 108 from Delhi, 80 from Maharashtra, 48 from West Bengal, 27 each from Haryana and Punjab, 21 each from Chhattisgarh and Kerala and 20 each from Gujarat and Rajasthan. Total 1,37,621 deaths reported so far in the country include 47,151 from Maharashtra followed by 11,778 from Karnataka, 11,712 from Tamil Nadu, 9,174 from Delhi, 8,424 from West Bengal, 7,761 from Uttar Pradesh, 6,992 from Andhra Pradesh, 4,807 from Punjab, 3,989 from Gujarat and 3,260 from Madhya Pradesh. The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities. "Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation. (With inputs from agencies)

Coronavirus caseload in India rises to 94.62 lakh with 31,118 new infections

As the world is battling the novel coronavirus, Japan had been safer from the deadly virus, as compared to other countries. However, another danger has taken over the Asian country.

With the danger of contracting COVID-19, majority of the countries went into a nationwide lockdown, which was followed by Japan too. However, unlike many others, Japan was able to contain the spread sooner than the rest of the world. Sadly, that has not eased the pressure of the locals who are struggling to pay their bills in the pandemic-hit economy.

As per the official statistics released, Japan has lost more people to suicide in the month of October alone, than to COVID-19 in the year 2020.

The monthly suicide figure increased to&nbsp;2,153 for the month of October, according to data released by Japan's National Police Agency. The figure has come as a shocking reminder of the effects of the novel coronavirus on one's mental health.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-japans-rising-suicide-rate-346567/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Japan recorded a death toll of nearly&nbsp;2,087 by coronavirus till date, the health ministry said. However, the reality is that while people were able to save themselves from contracting the deadly virus, they were unable to escape the adverse effects of the nationwide lockdown.

The government has implemented two lockdowns, to date. However, experts believe that since the intensity of the lockdowns was not that severe in Japan, other countries which have had stricter lockdowns — such as India, Italy, Pakistan, Australia — face a bigger threat of declining mental health. Japan is one of the rare countries that provides&nbsp;timely suicide data.&nbsp;

However, Japan's alarming rise in the suicide rate is not just because of the coronavirus. The locals are also struggling with&nbsp;long working hours in&nbsp;their professional lives and teenagers are struggling with increasing school pressure. In addition to social isolation, the stigma and stereotypes associated with mental health have also been cited as one of the main reasons for people choosing to end their lives.

This increase in the suicide rate has come as a reverse trend in the country. Japan's suicide rate had been decreasing in the past year and had reached about&nbsp;20,000 last year. However, the pandemic has resulted into an increase this year, which has worried the government.

One worrying fact observed in this data study is that the number of female suicide rate increased by almost&nbsp;83 per cent, and for men it increased by&nbsp;22 per cent. The locals believe this is because Japan has been ignoring women and their issues for too long and women often get pushed in the corner due to Japan's "survival of the fittest" thought process. A major reason behind such a massive increase in the female suicide rate is also the increasing domestic pressure of keeping the partners happy and satisfied, as well as making sure the children are healthy, fit and excelling in school. This pressure has increased in the pandemic, as many women have reported increased anxieties since the lockdowns.

As the world is battling the novel coronavirus, Japan had been safer from the deadly virus, as compared to other countries. However, another danger has taken over the Asian country.

As the world is battling the novel coronavirus, Japan had been safer from the deadly virus, as compared to other countries. However, another danger has taken over the Asian country. With the danger of contracting COVID-19, majority of the countries went into a nationwide lockdown, which was followed by Japan too. However, unlike many others, Japan was able to contain the spread sooner than the rest of the world. Sadly, that has not eased the pressure of the locals who are struggling to pay their bills in the pandemic-hit economy. As per the official statistics released, Japan has lost more people to suicide in the month of October alone, than to COVID-19 in the year 2020. The monthly suicide figure increased to 2,153 for the month of October, according to data released by Japan's National Police Agency. The figure has come as a shocking reminder of the effects of the novel coronavirus on one's mental health. × Japan recorded a death toll of nearly 2,087 by coronavirus till date, the health ministry said. However, the reality is that while people were able to save themselves from contracting the deadly virus, they were unable to escape the adverse effects of the nationwide lockdown. The government has implemented two lockdowns, to date. However, experts believe that since the intensity of the lockdowns was not that severe in Japan, other countries which have had stricter lockdowns — such as India, Italy, Pakistan, Australia — face a bigger threat of declining mental health. Japan is one of the rare countries that provides timely suicide data. However, Japan's alarming rise in the suicide rate is not just because of the coronavirus. The locals are also struggling with long working hours in their professional lives and teenagers are struggling with increasing school pressure. In addition to social isolation, the stigma and stereotypes associated with mental health have also been cited as one of the main reasons for people choosing to end their lives. This increase in the suicide rate has come as a reverse trend in the country. Japan's suicide rate had been decreasing in the past year and had reached about 20,000 last year. However, the pandemic has resulted into an increase this year, which has worried the government. One worrying fact observed in this data study is that the number of female suicide rate increased by almost 83 per cent, and for men it increased by 22 per cent. The locals believe this is because Japan has been ignoring women and their issues for too long and women often get pushed in the corner due to Japan's "survival of the fittest" thought process. A major reason behind such a massive increase in the female suicide rate is also the increasing domestic pressure of keeping the partners happy and satisfied, as well as making sure the children are healthy, fit and excelling in school. This pressure has increased in the pandemic, as many women have reported increased anxieties since the lockdowns.

More people died by suicide in October than from COVID-19 in 2020 in Japan

Coronavirus was first reported in late December 2019 in Wuhan's Hubei province in China. The deadly virus since then has infected more than 63.2 million people and led to over 1.47 million deaths around the world, according to John Hopkins University coronavirus resource centre. 
 
<a href="https://www.wionews.com/world/chinese-scientists-now-claim-coronavirus-originated-in-india-in-summer-2019-346039">Also read: Chinese scientists now claim coronavirus originated in India in summer 2019</a> 
 
Many reports in past have proved that China deliberately suppressed or destroyed evidence related to the coronavirus outbreak. Communist regime endangered other countries by silencing doctors and whistleblowers who spoke about the virus. If this was not enough, Beijing destroyed evidence of it in laboratories and also refused to provide live samples to international scientists who were working on a vaccine. 
 
<a href="https://www.wionews.com/opinions-blogs/coronavirus-spread-china-must-allow-global-probe-to-ascertain-origin-of-covid-19-291113">Also read: International survey shows China has lost international backing after the emergence of COVID-19</a> 
 
According to a report published in CNN, a document marked as "internal document, please keep confidential," local health authorities in the province of Hubei, where the virus was first detected, list a total of 5918 newly detected cases on February 10, more than double the official the public number of confirmed cases, breaking down the total into a variety of subcategories.

A whistleblower, who worked in the Chinese health care system, provided 117 pages of internal documents from the Hubei Provincial Center for Disease Control and Prevention (CDC) to CNN.&nbsp;

The files, which CNN had verified by six experts, showed how the region struggled to manage the coronavirus between October 2019 and April 2020 – a critical time period in which the virus spread from China to cause a worldwide pandemic.&nbsp;

There are many theories around the origin of the virus, from being leaked of the Wuhan virus Lab to many of them linking it to the wet market in Wuhan.

The reason for the origin of the virus remains unknown, though. Local health authorities initially thought the patients had fallen ill through exposure to common infection source in the market and ruled out the pathogen as contagious until January 20.

The Xi Jinping government has been rejecting&nbsp;accusations made by the United States and other Western governments that it deliberately concealed information relating to the virus, maintaining that it has been upfront since the beginning of the outbreak.

Should China be held accountable for mishandling the deadly virus at the initial stage, it is the answer that the world is looking for.

(With inputs from agencies)

Coronavirus was first reported in late December 2019 in Wuhan's Hubei province in China. The deadly virus since then has infected more than 63.2 million people and led to over 1.

Coronavirus was first reported in late December 2019 in Wuhan's Hubei province in China. The deadly virus since then has infected more than 63.2 million people and led to over 1.47 million deaths around the world, according to John Hopkins University coronavirus resource centre. Also read: Chinese scientists now claim coronavirus originated in India in summer 2019 Many reports in past have proved that China deliberately suppressed or destroyed evidence related to the coronavirus outbreak. Communist regime endangered other countries by silencing doctors and whistleblowers who spoke about the virus. If this was not enough, Beijing destroyed evidence of it in laboratories and also refused to provide live samples to international scientists who were working on a vaccine. Also read: International survey shows China has lost international backing after the emergence of COVID-19 According to a report published in CNN, a document marked as "internal document, please keep confidential," local health authorities in the province of Hubei, where the virus was first detected, list a total of 5918 newly detected cases on February 10, more than double the official the public number of confirmed cases, breaking down the total into a variety of subcategories. A whistleblower, who worked in the Chinese health care system, provided 117 pages of internal documents from the Hubei Provincial Center for Disease Control and Prevention (CDC) to CNN. The files, which CNN had verified by six experts, showed how the region struggled to manage the coronavirus between October 2019 and April 2020 – a critical time period in which the virus spread from China to cause a worldwide pandemic. There are many theories around the origin of the virus, from being leaked of the Wuhan virus Lab to many of them linking it to the wet market in Wuhan. The reason for the origin of the virus remains unknown, though. Local health authorities initially thought the patients had fallen ill through exposure to common infection source in the market and ruled out the pathogen as contagious until January 20. The Xi Jinping government has been rejecting accusations made by the United States and other Western governments that it deliberately concealed information relating to the virus, maintaining that it has been upfront since the beginning of the outbreak. Should China be held accountable for mishandling the deadly virus at the initial stage, it is the answer that the world is looking for. (With inputs from agencies)

Leaked documents show China bluntly lied about Covid-19 and mishandled early pandemic

India may not need to vaccinate all of its 1.3 billion people if it manages to inoculate a critical mass and break the transmission of the coronavirus, senior government officials said on Tuesday. 
 
Indian Prime Minister Narendra Modi, who toured the facilities of three vaccine makers over the weekend, has emphasized the importance of a vaccine to rein in COVID-19. 
 
In October, he said that the government was preparing to reach every single citizen as soon as a vaccine was ready. 
 
World Health Organization experts have pointed to a 65%-70% vaccine coverage rate as sufficient to reach population immunity. 
 
"The government has never spoken about vaccinating the entire country," Rajesh Bhushan, the top bureaucrat in India`s federal health ministry, told a news conference on Tuesday without reference to Modi. 
 
India currently has the world`s second-highest number of coronavirus infections, behind only the United States, with 9.46 million cases and 137,621 deaths. 
 
India recorded 31,118 new coronavirus cases on Tuesday, the lowest daily tally since Nov. 17, data from the health ministry showed. 
 
"...If we are able to vaccinate a critical mass of people, and break that virus transmission, then we may not have to vaccinate the entire population," Balram Bhargava, Director General of the state-run Indian Council Of Medical Research, said at the press briefing. 
 
India`s plan to roll out a COVID-19 shot in the first few months of 2021 wouldn`t be impacted by an alleged adverse reaction during AstraZeneca`s COVID-19 vaccine trial, Bhushan said. 
 
A 40-year-old Indian man said in a complaint over the weekend that he had suffered serious “neurological and psychological” symptoms after receiving the vaccine in a trial being run by the British drugmaker’s partner, Serum Institute of India. 
 
The incident is currently under investigation.

India may not need to vaccinate all of its 1.3 billion people if it manages to inoculate a critical mass and break the transmission of the coronavirus, senior government officials said on Tuesday.

India may not need to vaccinate all of its 1.3 billion people if it manages to inoculate a critical mass and break the transmission of the coronavirus, senior government officials said on Tuesday. Indian Prime Minister Narendra Modi, who toured the facilities of three vaccine makers over the weekend, has emphasized the importance of a vaccine to rein in COVID-19. In October, he said that the government was preparing to reach every single citizen as soon as a vaccine was ready. World Health Organization experts have pointed to a 65%-70% vaccine coverage rate as sufficient to reach population immunity. "The government has never spoken about vaccinating the entire country," Rajesh Bhushan, the top bureaucrat in India`s federal health ministry, told a news conference on Tuesday without reference to Modi. India currently has the world`s second-highest number of coronavirus infections, behind only the United States, with 9.46 million cases and 137,621 deaths. India recorded 31,118 new coronavirus cases on Tuesday, the lowest daily tally since Nov. 17, data from the health ministry showed. "...If we are able to vaccinate a critical mass of people, and break that virus transmission, then we may not have to vaccinate the entire population," Balram Bhargava, Director General of the state-run Indian Council Of Medical Research, said at the press briefing. India`s plan to roll out a COVID-19 shot in the first few months of 2021 wouldn`t be impacted by an alleged adverse reaction during AstraZeneca`s COVID-19 vaccine trial, Bhushan said. A 40-year-old Indian man said in a complaint over the weekend that he had suffered serious “neurological and psychological” symptoms after receiving the vaccine in a trial being run by the British drugmaker’s partner, Serum Institute of India. The incident is currently under investigation.

India says may not need to vaccinate entire population to control COVID-19

A 101-year-old Italian woman has been through a lot. After surviving the Spanish Flu, the Second World War, she has now become a COVID warrior.&nbsp;

<div id="fb-root">Think this is too much? Beat this: She beat COVID-19, not once but thrice!</div>
<script async defer crossorigin="anonymous" src="https://connect.facebook.net/en_GB/sdk.js#xfbml=1&version=v9.0" nonce="LOfNaNE1"></script>

Maria Orsingher’s case has baffled doctors in Italy. She first tested positive for COVID-19 in February.

Also read:&nbsp;<a href="http://13.235.153.162/world/chinese-scientists-now-claim-coronavirus-originated-in-india-in-summer-2019-346039" hreflang="en">Chinese scientists now claim coronavirus originated in India in summer 2019</a>

Her daughter Carla told RT that Orsingher was hospitalised in Sondalo in February. After her recovery, the doctors told the daughter that she had never seen anybody as old as her triumph and recover from COVID-19 so conveniently.&nbsp;

She did not require breathing assistance, and did not develop fever as well.

In July, the elderly woman celebrated her 101st birthday. Following this, she developed a fever in September, after which she was hospitalised. There after, she tested positive for COVID-19 again, and was then treated for 18 days.

<div class="fb-post" data-href="https://www.facebook.com/LombardiaNotizieOnline/posts/3683335791725633" data-show-text="true" data-width="">
<blockquote cite="https://www.facebook.com/LombardiaNotizieOnline/posts/3683335791725633" class="fb-xfbml-parse-ignore">
#BuoneNotizie Maria Orsingher, 101 anni, ha sconfitto la Spagnola è sopravvissuta alla guerra e ora, finalmente, ha...
Posted by <a href="https://www.facebook.com/LombardiaNotizieOnline/">Lombardia Notizie Online</a> on&nbsp;<a href="https://www.facebook.com/LombardiaNotizieOnline/posts/3683335791725633">Sunday, 29 November 2020</a></blockquote>
</div>

According to local media, her hospitalisation was more precautionary than necessary, given her age and risks.

However, COVID was not done with her. She tested positive for COVID-19 again last week. Fortunately, she did not develop any symptoms this time.

Also read:&nbsp;<a href="http://13.235.153.162/world/with-frozen-food-clampdown-china-questions-theory-of-coronavirus-outbreak-in-wuhan-346003" hreflang="en">With frozen food clampdown, China questions theory of coronavirus outbreak in Wuhan</a>

Orsingher is recovering in bed.&nbsp; She is also deaf, so is unable to communicate with her kids. Maria Orsingher was born in Gaggio, Italy on July 21, 1919.

As if enduring the Spanish Flu pandemic wasn’t enough, she also survived COVID-19 twice, and is expected to recover again.

Her daughters told RT that the doctors and caretakers remain amazed. In a span of nine months, their mother has tested positive thrice, and tested negative thrice.

A 101-year-old Italian woman has been through a lot. After surviving the Spanish Flu, the Second World War, she has now become a COVID warrior. Think this is too much?

A 101-year-old Italian woman has been through a lot. After surviving the Spanish Flu, the Second World War, she has now become a COVID warrior. Think this is too much? Beat this: She beat COVID-19, not once but thrice! Maria Orsingher’s case has baffled doctors in Italy. She first tested positive for COVID-19 in February. Also read: Chinese scientists now claim coronavirus originated in India in summer 2019 Her daughter Carla told RT that Orsingher was hospitalised in Sondalo in February. After her recovery, the doctors told the daughter that she had never seen anybody as old as her triumph and recover from COVID-19 so conveniently. She did not require breathing assistance, and did not develop fever as well. In July, the elderly woman celebrated her 101st birthday. Following this, she developed a fever in September, after which she was hospitalised. There after, she tested positive for COVID-19 again, and was then treated for 18 days. #BuoneNotizie Maria Orsingher, 101 anni, ha sconfitto la Spagnola è sopravvissuta alla guerra e ora, finalmente, ha... Posted by Lombardia Notizie Online on Sunday, 29 November 2020 According to local media, her hospitalisation was more precautionary than necessary, given her age and risks. However, COVID was not done with her. She tested positive for COVID-19 again last week. Fortunately, she did not develop any symptoms this time. Also read: With frozen food clampdown, China questions theory of coronavirus outbreak in Wuhan Orsingher is recovering in bed. She is also deaf, so is unable to communicate with her kids. Maria Orsingher was born in Gaggio, Italy on July 21, 1919. As if enduring the Spanish Flu pandemic wasn’t enough, she also survived COVID-19 twice, and is expected to recover again. Her daughters told RT that the doctors and caretakers remain amazed. In a span of nine months, their mother has tested positive thrice, and tested negative thrice.

After surviving Spanish Flu, 101-year-old Italian woman catches COVID-19 thrice!

Coronavirus, Trump and China: What made 2020 an unforgettable year

Across the world are applying for emergency use authorization for vaccine against coronavirus. What exactly is this permit and how it may granted ?

Final permit granted only after trial completion

China has provided North Korean leader Kim Jong Un and his family with an experimental coronavirus vaccine, a US analyst said on Tuesday, citing two unidentified Japanese intelligence sources.

Harry Kazianis, a North Korea expert at the Center for the National Interest think tank in Washington, said the Kims and several senior North Korean officials had been vaccinated.

It was unclear which company had supplied its drug candidate to the Kims and whether it had proven to be safe, he added.

"Kim Jong Un and multiple other high-ranking officials within the Kim family and leadership network have been vaccinated for coronavirus within the last two to three weeks thanks to a vaccine candidate supplied by the Chinese government," Kazianis wrote in an article for online outlet 19FortyFive.

Citing US medical scientist Peter J. Hotez, he said at least three Chinese companies were developing a coronavirus vaccine, including Sinovac Biotech Ltd, CanSinoBio and Sinophram Group.

Sinophram says its candidate has been used by nearly one million people in China, although none of the firms was known to have publicly launched Phase 3 clinical trials of their experimental COVID-19 drugs.

Some experts doubted that Kim would use an experimental vaccine.

"Even if a Chinese vaccine had already been approved, no drug is perfect and he would not take that risk when he has numerous shelters which can ensure almost complete isolation," said Choi Jung-hun, an infectious disease expert who defected from North Korea to the South in 2012.

Mark Barry, an East Asia analyst and associate editor of the International Journal on World Peace, said Kim would prefer proven European vaccines to one supplied by Beijing.

"The risk is too great. But he's happy to get Chinese personal protective equipment," Barry said on Twitter.

North Korea has not confirmed any coronavirus infections, but South Korea's National Intelligence Service (NIS) has said an outbreak there cannot be ruled out as the country had trade and people-to-people exchanges with China - the source of the pandemic - before shutting the border in late January.

Microsoft said last month that two North Korean hacking groups had tried to break into the network of vaccine developers in multiple countries, without specifying the companies targeted. Sources told Reuters they included British drugmaker AstraZeneca.

The NIS said last week it had foiled North Korea's attempts to hack into South Korean COVID-19 vaccine makers.

China has provided North Korean leader Kim Jong Un and his family with an experimental coronavirus vaccine, a US analyst said on Tuesday, citing two unidentified Japanese intelligence sources.

China has provided North Korean leader Kim Jong Un and his family with an experimental coronavirus vaccine, a US analyst said on Tuesday, citing two unidentified Japanese intelligence sources. Harry Kazianis, a North Korea expert at the Center for the National Interest think tank in Washington, said the Kims and several senior North Korean officials had been vaccinated. It was unclear which company had supplied its drug candidate to the Kims and whether it had proven to be safe, he added. "Kim Jong Un and multiple other high-ranking officials within the Kim family and leadership network have been vaccinated for coronavirus within the last two to three weeks thanks to a vaccine candidate supplied by the Chinese government," Kazianis wrote in an article for online outlet 19FortyFive. Citing US medical scientist Peter J. Hotez, he said at least three Chinese companies were developing a coronavirus vaccine, including Sinovac Biotech Ltd, CanSinoBio and Sinophram Group. Sinophram says its candidate has been used by nearly one million people in China, although none of the firms was known to have publicly launched Phase 3 clinical trials of their experimental COVID-19 drugs. Some experts doubted that Kim would use an experimental vaccine. "Even if a Chinese vaccine had already been approved, no drug is perfect and he would not take that risk when he has numerous shelters which can ensure almost complete isolation," said Choi Jung-hun, an infectious disease expert who defected from North Korea to the South in 2012. Mark Barry, an East Asia analyst and associate editor of the International Journal on World Peace, said Kim would prefer proven European vaccines to one supplied by Beijing. "The risk is too great. But he's happy to get Chinese personal protective equipment," Barry said on Twitter. North Korea has not confirmed any coronavirus infections, but South Korea's National Intelligence Service (NIS) has said an outbreak there cannot be ruled out as the country had trade and people-to-people exchanges with China - the source of the pandemic - before shutting the border in late January. Microsoft said last month that two North Korean hacking groups had tried to break into the network of vaccine developers in multiple countries, without specifying the companies targeted. Sources told Reuters they included British drugmaker AstraZeneca. The NIS said last week it had foiled North Korea's attempts to hack into South Korean COVID-19 vaccine makers.

China gave Covid-19 vaccine candidate to North Korea's Kim Jong Un: US analyst

Russia announced Sputnik V as the world’s first successful coronavirus vaccine earlier in August. Since then, authorities have claimed that they have inoculated many people, even in President Putin’s close circles.

On Monday, a hospital in southern Moscow claimed that it had received the first batch of Sputnik V vaccines for public use and that they had inoculated the local population last week.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/coronavirus-pandemic-clinical-trials-for-sputnik-v-to-resume-and-to-be-held-in-india-336124/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Countries around the world are currently racing to roll out vaccines. US drugmakers Moderna and Pfizer claim that their vaccines are 94 per cent effective.&nbsp;Sputnik V makers claim that it is 92 per cent effective in protecting people from the virus.

Also read:&nbsp;<a href="http://13.235.153.162/world/sputnik-v-can-boost-efficacy-of-astrazeneca-vaccine-russian-research-centre-345769" hreflang="en">Sputnik V can boost efficacy of AstraZeneca vaccine: Russian research centre</a>

The Central City Hospital in Domodedovo announced on its website that people who want the COVID-19 shot should register on a government website in advance, and also bring with them a negative COVID-19 test result, and government identification.

Since September, cases in Russia have surged. But authorities have not imposed a lockdown, claiming sporadic measures are successful in containing the virus.

Also read:&nbsp;<a href="http://13.235.153.162/world/sputnik-v-coronavirus-vaccine-to-cost-less-than-10-per-dose-russia-345138" hreflang="en">Sputnik V coronavirus vaccine to cost less than $10 per dose: Russia</a>

On Monday, Russia inducted 26,338 cases of COVID-19. In Moscow alone, 6,511 cases were recorded, and 3,691 in St Petersburg. This will take the national total to 2,295,654 since the beginning of the pandemic.

In the last 24 hours, Russia reported 368 coronavirus-related deaths, taking the death toll to 39,895.

Today, Moderna is seeking emergency authorisation of its vaccine in the United States and European Union, which would enable it to roll out the vaccines on urgent basis. Additionally, Pfizer vaccine may be rolled out to National Health Services in the United Kingdom as early as the first week of December.&nbsp;

Russia announced Sputnik V as the world’s first successful coronavirus vaccine earlier in August. Since then, authorities have claimed that they have inoculated many people, even in President Putin’s close circles.

Russia announced Sputnik V as the world’s first successful coronavirus vaccine earlier in August. Since then, authorities have claimed that they have inoculated many people, even in President Putin’s close circles. On Monday, a hospital in southern Moscow claimed that it had received the first batch of Sputnik V vaccines for public use and that they had inoculated the local population last week. Countries around the world are currently racing to roll out vaccines. US drugmakers Moderna and Pfizer claim that their vaccines are 94 per cent effective. Sputnik V makers claim that it is 92 per cent effective in protecting people from the virus. Also read: Sputnik V can boost efficacy of AstraZeneca vaccine: Russian research centre The Central City Hospital in Domodedovo announced on its website that people who want the COVID-19 shot should register on a government website in advance, and also bring with them a negative COVID-19 test result, and government identification. Since September, cases in Russia have surged. But authorities have not imposed a lockdown, claiming sporadic measures are successful in containing the virus. Also read: Sputnik V coronavirus vaccine to cost less than $10 per dose: Russia On Monday, Russia inducted 26,338 cases of COVID-19. In Moscow alone, 6,511 cases were recorded, and 3,691 in St Petersburg. This will take the national total to 2,295,654 since the beginning of the pandemic. In the last 24 hours, Russia reported 368 coronavirus-related deaths, taking the death toll to 39,895. Today, Moderna is seeking emergency authorisation of its vaccine in the United States and European Union, which would enable it to roll out the vaccines on urgent basis. Additionally, Pfizer vaccine may be rolled out to National Health Services in the United Kingdom as early as the first week of December.

Russian hospital claims to have administered Sputnik V to civilians last week

China has claimed that just because the first COVID-19 case was detected from the Wuhan doesn't mean that it originated from the Chinese city itself. China's state media has also started reporting that traces of the virus were found on the number of imported food products from different countries including India.

China claims, COVID-19 virus originated outside the country

India is looking to be self-reliant in the development and production of COVID-19 vaccine as the world races to develop a vaccine against the disease.While at least five pharmaceutical companies of India are engaged in vaccine development, Serum Institute in Pune has been chosen for mass production of Covishield vaccine developed by Oxford -Astra Zeneca.

A total of 10 vaccine candidates have been supported by Department of Biotechnology so far at both academia and industry and as on date, five vaccine candidates are in the human trials stage.

A PMO release said the government has initiated a robust COVID-19 vaccine manufacturing and delivery ecosystem to meet the demand.It said Prime Minister Narendra Modi has been personally monitoring the progress of vaccine development in India.

He visited facilities of Zydus in Ahmedabad, Serum Institute in Pune and Bharat Biotech in Hyderabad on Saturday. The Prime Minister held a virtual review of the progress of indigenous vaccine development undertaken by Gennova Biopharma of Pune and Biological E and Dr Reddy`s Laboratories in Hyderabad today.

PM Modi asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters. He also suggested that they should take extra efforts to inform people in simple language about the vaccine and related matters such as its efficacy.

Matters relating to logistics, transport, cold chain in respect of delivering the vaccines were also discussed.The government has announced a stimulus package of Rs 900 crore for mission COVID Suraksha to promote indigenous vaccine development.

The release said that COVID-19 Vaccine Development Mission with end-to-end focus from preclinical development, through clinical development and manufacturing and regulatory facilitation for deployment, would consolidate all available and funded resources towards accelerated product development.

"The other important objective will be supporting the development of common harmonized protocols, training, data management systems, regulatory submissions, internal and external quality management systems and accreditations," it said.

The release said that the grant will be provided to the Department of Biotechnology for Research and Development of Indian COVID-19 vaccines and ensure that they are fast-tracked for introduction in public health systems, subject to all regulatory clearances.

Ambassadors of 100 countries are scheduled to arrive in Pune on December 4 to visit Serum Institute of India and Gennova Biopharma.

The release said Sweden has already acknowledged India`s role as the "pharmacy of the world" and is focusing on expanding bilateral cooperation in the areas of health and life sciences in view of the Coronavirus pandemic.

It said Luxembourg-based company B Systems is partnering with India to produce portable vaccine refrigeration equipment, which will address the issue of vaccine distribution in India.PM Modi had held a virtual summit with his Luxembourg counterpart Xavier Bettel on November 19 during which stress was laid on intensifying bilateral cooperation.

India is looking to be self-reliant in the development and production of COVID-19 vaccine as the world races to develop a vaccine against the disease.While at least five pharmaceutical companies of India are engaged in vaccine development, Serum Institute in Pune has been chosen for mass production of Covishield vaccine developed by Oxford -Astra Zeneca.

India is looking to be self-reliant in the development and production of COVID-19 vaccine as the world races to develop a vaccine against the disease.While at least five pharmaceutical companies of India are engaged in vaccine development, Serum Institute in Pune has been chosen for mass production of Covishield vaccine developed by Oxford -Astra Zeneca. A total of 10 vaccine candidates have been supported by Department of Biotechnology so far at both academia and industry and as on date, five vaccine candidates are in the human trials stage. A PMO release said the government has initiated a robust COVID-19 vaccine manufacturing and delivery ecosystem to meet the demand.It said Prime Minister Narendra Modi has been personally monitoring the progress of vaccine development in India. He visited facilities of Zydus in Ahmedabad, Serum Institute in Pune and Bharat Biotech in Hyderabad on Saturday. The Prime Minister held a virtual review of the progress of indigenous vaccine development undertaken by Gennova Biopharma of Pune and Biological E and Dr Reddy`s Laboratories in Hyderabad today. PM Modi asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters. He also suggested that they should take extra efforts to inform people in simple language about the vaccine and related matters such as its efficacy. Matters relating to logistics, transport, cold chain in respect of delivering the vaccines were also discussed.The government has announced a stimulus package of Rs 900 crore for mission COVID Suraksha to promote indigenous vaccine development. The release said that COVID-19 Vaccine Development Mission with end-to-end focus from preclinical development, through clinical development and manufacturing and regulatory facilitation for deployment, would consolidate all available and funded resources towards accelerated product development. "The other important objective will be supporting the development of common harmonized protocols, training, data management systems, regulatory submissions, internal and external quality management systems and accreditations," it said. The release said that the grant will be provided to the Department of Biotechnology for Research and Development of Indian COVID-19 vaccines and ensure that they are fast-tracked for introduction in public health systems, subject to all regulatory clearances. Ambassadors of 100 countries are scheduled to arrive in Pune on December 4 to visit Serum Institute of India and Gennova Biopharma. The release said Sweden has already acknowledged India`s role as the "pharmacy of the world" and is focusing on expanding bilateral cooperation in the areas of health and life sciences in view of the Coronavirus pandemic. It said Luxembourg-based company B Systems is partnering with India to produce portable vaccine refrigeration equipment, which will address the issue of vaccine distribution in India.PM Modi had held a virtual summit with his Luxembourg counterpart Xavier Bettel on November 19 during which stress was laid on intensifying bilateral cooperation.

India looking to be self-reliant in development, production of vaccine against COVID-19

Vietnam confirmed on Monday its first locally transmitted case of the coronavirus in nearly three months, after the infection of a man related to a flight attendant who had tested positive after returning from Japan two weeks ago. 
 
The country`s health minister ordered provinces and state agencies to tighten screening and controls and contact tracing efforts were launched after the 32-year-old man was confirmed as the first reported domestic infection in 89 days. 
 
With its strict quarantine and tracking measures, Vietnam has managed to quickly contain its coronavirus outbreaks, allowing it to resume its economic activities earlier than much of Asia. 
 
Vietnam crushed its first wave of coronavirus infections in April and went nearly 100 days without local transmission until the virus remerged and was quickly contained in the central city of Danang in July. 
 
Authorities said the latest case had taught at language-learning centres and been to cafes and karaoke bars since his exposure to the flight attendant. Those places had since been closed. 
 
Vietnam has so far recorded 1,347 coronavirus cases, 655 of which it said were imported. The country has reported an average of five of those cases a day recently. 
 
It has effectively closed its borders to combat the coronavirus but has allowed some business travellers and those with foreign expertise to enter on special flights provided they undergo quarantine. 
 
Monday`s case came days after the health ministry warned of a new outbreak among the community as the cold season has begun. 
 
"The COVID-19 situation remains complicated," Health Minister Nguyen Thanh Long said last week. 
 
"The disease has returned in many parts of the world in winter time."

Vietnam confirmed on Monday its first locally transmitted case of the coronavirus in nearly three months, after the infection of a man related to a flight attendant who had tested positive after returning from Japan two weeks ago.

Vietnam confirmed on Monday its first locally transmitted case of the coronavirus in nearly three months, after the infection of a man related to a flight attendant who had tested positive after returning from Japan two weeks ago. The country`s health minister ordered provinces and state agencies to tighten screening and controls and contact tracing efforts were launched after the 32-year-old man was confirmed as the first reported domestic infection in 89 days. With its strict quarantine and tracking measures, Vietnam has managed to quickly contain its coronavirus outbreaks, allowing it to resume its economic activities earlier than much of Asia. Vietnam crushed its first wave of coronavirus infections in April and went nearly 100 days without local transmission until the virus remerged and was quickly contained in the central city of Danang in July. Authorities said the latest case had taught at language-learning centres and been to cafes and karaoke bars since his exposure to the flight attendant. Those places had since been closed. Vietnam has so far recorded 1,347 coronavirus cases, 655 of which it said were imported. The country has reported an average of five of those cases a day recently. It has effectively closed its borders to combat the coronavirus but has allowed some business travellers and those with foreign expertise to enter on special flights provided they undergo quarantine. Monday`s case came days after the health ministry warned of a new outbreak among the community as the cold season has begun. "The COVID-19 situation remains complicated," Health Minister Nguyen Thanh Long said last week. "The disease has returned in many parts of the world in winter time."

Vietnam reports first locally transmitted COVID-19 case in 89 days

Prime Minister Narendra Modi on Monday appreciated the efforts by scientists in Gennova Biopharmaceuticals Ltd, Biological E Ltd and Dr Reddys Laboratories Ltd to come out with a vaccine solution to tackle COVID-19.&nbsp;

During his virtual meetings with 3 teams- Gennova Biopharmaceuticals Ltd, Pune, Biological E Ltd, Hyderabad and Dr Reddys Laboratories Ltd, Hyderabad- that are working on developing and manufacturing coronavirus vaccine, the Prime Minister discussed the potential of various platforms for COVID-19 vaccine development.

According to the Prime Minister's Office (PMO), PM Modi also suggested that the companies should take extra efforts to inform the general public in simple language about the vaccine and related matters such as its efficacy. He also asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters.

Matters relating to logistics, transport, cold chain in respect of delivering the vaccines were also discussed at the meetings. PMO said that all the vaccine candidates discussed are at different stages of trials and detailed data and results are expected early next year onwards.

The Prime Minister advised all the departments concerned to engage with the manufacturers and seek to resolve matters so that the efforts by these companies bear fruit in order to serve the needs of the country and the entire world. On Saturday, Prime Minister Modi had visited the Serum Institute of India in Pune as part of efforts to get a first-hand perspective of the preparations, challenges, and roadmap in India's endeavour to vaccinate its citizens against COVID-19.

He had also visited Zydus Biotech Park in Ahmedabad and Bharat Biotech facility at Hyderabad on Saturday as part of his three-city visit to personally review the vaccine development and manufacturing process against COVID-19. India's coronavirus tally breached the 94-lakh mark after 38,772 new infections reported in the last 24 hours, according to the Union Ministry of Health and Family Welfare's data on Monday.

The overall coronavirus cases reached 94,31,692 including 4,46,952 active cases and 88,47,600 recoveries. With 443 new deaths, the cumulative toll mounted to 1,37,139.

Prime Minister Narendra Modi on Monday appreciated the efforts by scientists in Gennova Biopharmaceuticals Ltd, Biological E Ltd and Dr Reddys Laboratories Ltd to come out with a vaccine solution to tackle COVID-19.

Prime Minister Narendra Modi on Monday appreciated the efforts by scientists in Gennova Biopharmaceuticals Ltd, Biological E Ltd and Dr Reddys Laboratories Ltd to come out with a vaccine solution to tackle COVID-19. During his virtual meetings with 3 teams- Gennova Biopharmaceuticals Ltd, Pune, Biological E Ltd, Hyderabad and Dr Reddys Laboratories Ltd, Hyderabad- that are working on developing and manufacturing coronavirus vaccine, the Prime Minister discussed the potential of various platforms for COVID-19 vaccine development. According to the Prime Minister's Office (PMO), PM Modi also suggested that the companies should take extra efforts to inform the general public in simple language about the vaccine and related matters such as its efficacy. He also asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters. Matters relating to logistics, transport, cold chain in respect of delivering the vaccines were also discussed at the meetings. PMO said that all the vaccine candidates discussed are at different stages of trials and detailed data and results are expected early next year onwards. The Prime Minister advised all the departments concerned to engage with the manufacturers and seek to resolve matters so that the efforts by these companies bear fruit in order to serve the needs of the country and the entire world. On Saturday, Prime Minister Modi had visited the Serum Institute of India in Pune as part of efforts to get a first-hand perspective of the preparations, challenges, and roadmap in India's endeavour to vaccinate its citizens against COVID-19. He had also visited Zydus Biotech Park in Ahmedabad and Bharat Biotech facility at Hyderabad on Saturday as part of his three-city visit to personally review the vaccine development and manufacturing process against COVID-19. India's coronavirus tally breached the 94-lakh mark after 38,772 new infections reported in the last 24 hours, according to the Union Ministry of Health and Family Welfare's data on Monday. The overall coronavirus cases reached 94,31,692 including 4,46,952 active cases and 88,47,600 recoveries. With 443 new deaths, the cumulative toll mounted to 1,37,139.

PM Modi appreciates scientists' efforts to come out with vaccine solution to combat COVID-19

A Chinese factory owned by South Korean semiconductor giant SK Hynix Inc halted operations on Sunday after a plant worker was found to have an asymptomatic infection of the novel coronavirus, the official news agency Xinhua reported.

The Korean worker based at the plant in Chongqing city since February had departed on Thursday for South Korea, Xinhua reported.

He was tested at Incheon airport in Seoul and confirmed positive for the novel coronavirus on Saturday, it reported.

All factory staff as well as staff and recent guests at the hotel where the worker lived have been isolated and given nucleic acid tests, the news agency said.

"We`re cooperating with the local government on their containment efforts, and at the same time trying to resume production as soon as possible," said a spokesman at SK Hynix.

He declined to comment on the impact the suspension would have.

SK Hynix, the world`s No.2 memory chip maker, employs about 2,700 workers in the Chongqing facility, including some Koreans.

The city has carried out nucleic acid tests on 3,283 people, with 2,674 found negative, Xinhua said. Almost 500 environmental samples had also been collected, and all found negative.

China reported 11 new coronavirus cases in the mainland for Nov. 28, compared with six cases a day earlier, the health authority said earlier on Sunday.

All of the new infections were imported cases, the National Health Commission said in a statement. There were no new deaths.

China also reported 10 new asymptomatic patients, compared with four a day earlier.

As of Nov. 28, mainland China had a total of 86,512 confirmed coronavirus cases, it said.

China`s death toll from the coronavirus remained unchanged at 4,634.

A Chinese factory owned by South Korean semiconductor giant SK Hynix Inc halted operations on Sunday after a plant worker was found to have an asymptomatic infection of the novel coronavirus, the official news agency Xinhua reported.

A Chinese factory owned by South Korean semiconductor giant SK Hynix Inc halted operations on Sunday after a plant worker was found to have an asymptomatic infection of the novel coronavirus, the official news agency Xinhua reported. The Korean worker based at the plant in Chongqing city since February had departed on Thursday for South Korea, Xinhua reported. He was tested at Incheon airport in Seoul and confirmed positive for the novel coronavirus on Saturday, it reported. All factory staff as well as staff and recent guests at the hotel where the worker lived have been isolated and given nucleic acid tests, the news agency said. "We`re cooperating with the local government on their containment efforts, and at the same time trying to resume production as soon as possible," said a spokesman at SK Hynix. He declined to comment on the impact the suspension would have. SK Hynix, the world`s No.2 memory chip maker, employs about 2,700 workers in the Chongqing facility, including some Koreans. The city has carried out nucleic acid tests on 3,283 people, with 2,674 found negative, Xinhua said. Almost 500 environmental samples had also been collected, and all found negative. China reported 11 new coronavirus cases in the mainland for Nov. 28, compared with six cases a day earlier, the health authority said earlier on Sunday. All of the new infections were imported cases, the National Health Commission said in a statement. There were no new deaths. China also reported 10 new asymptomatic patients, compared with four a day earlier. As of Nov. 28, mainland China had a total of 86,512 confirmed coronavirus cases, it said. China`s death toll from the coronavirus remained unchanged at 4,634.

China halts operation at Korean chip plant after worker tests positive for coronavirus

The United Kingdom is eyeing the approval of Pfizer and BioNTech SE’s COVID-19 vaccine as early as next week. Reports claim that workers of the National Health Service (NHS) in Britain could receive the vaccination&nbsp;by December 7.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/uk-regulatory-to-study-aztrazeneca-vaccine-346157/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Recently, Pfizer announced that its COVID-19 vaccine is 95 per cent effective, making it a promising&nbsp;candidate for mass inoculation alongside Moderna and Oxford candidates.

As of now, the UK has already ordered 40 million doses of COVID-19 vaccines. If followed through, the country would receive the first batch of vaccines by the first week of December.

Also read:&nbsp;<a href="http://13.235.153.162/world/uk-nearly-1300-people-wrongfully-given-positive-results-for-covid-19-346132" hreflang="en">UK: Nearly 1,300 people wrongfully given positive results for COVID-19</a>

On November 20, the UK had urged its medical regulator - the Medicines and Healthcare Products Regulatory Agency (MHRA) to test the viability of the Pfizer vaccine.

The MHRA is also in the process of ascertaining the safety imbued not only in Pfizer but also in Oxford University and AstraZeneca’s COVID-19 vaccine. Pfizer and BioNTech started conducting Phase 3 trials of their experimental vaccine by July.

Also read:&nbsp;<a href="http://13.235.153.162/world/uk-says-next-week-very-significant-for-brexit-deal-urges-eu-to-exercise-pragmatism-346236" hreflang="en">UK says next week 'very significant' for Brexit deal, urges EU to exercise pragmatism</a>

If the emergency use authorisation is provided to the vaccine, it will mark the first mass rollout of the vaccine in the West. Boris Johnson, the British Prime Minister on Sunday assigned minister Nadhim Zahawi to supervise inoculation in the United Kingdom.

The NHS workers will be the first ones to receive the vaccination in Britain.&nbsp; So far, COVID-19 has claimed over 58,000 lives in the UK. Over 16 lakh cases of the virus have been confirmed in the UK so far.

The United Kingdom is eyeing the approval of Pfizer and BioNTech SE’s COVID-19 vaccine as early as next week. Reports claim that workers of the National Health Service (NHS) in Britain could receive the vaccination by December 7.

The United Kingdom is eyeing the approval of Pfizer and BioNTech SE’s COVID-19 vaccine as early as next week. Reports claim that workers of the National Health Service (NHS) in Britain could receive the vaccination by December 7. Recently, Pfizer announced that its COVID-19 vaccine is 95 per cent effective, making it a promising candidate for mass inoculation alongside Moderna and Oxford candidates. As of now, the UK has already ordered 40 million doses of COVID-19 vaccines. If followed through, the country would receive the first batch of vaccines by the first week of December. Also read: UK: Nearly 1,300 people wrongfully given positive results for COVID-19 On November 20, the UK had urged its medical regulator - the Medicines and Healthcare Products Regulatory Agency (MHRA) to test the viability of the Pfizer vaccine. The MHRA is also in the process of ascertaining the safety imbued not only in Pfizer but also in Oxford University and AstraZeneca’s COVID-19 vaccine. Pfizer and BioNTech started conducting Phase 3 trials of their experimental vaccine by July. Also read: UK says next week 'very significant' for Brexit deal, urges EU to exercise pragmatism If the emergency use authorisation is provided to the vaccine, it will mark the first mass rollout of the vaccine in the West. Boris Johnson, the British Prime Minister on Sunday assigned minister Nadhim Zahawi to supervise inoculation in the United Kingdom. The NHS workers will be the first ones to receive the vaccination in Britain. So far, COVID-19 has claimed over 58,000 lives in the UK. Over 16 lakh cases of the virus have been confirmed in the UK so far.

Healthcare workers in UK could receive Pfizer's COVID-19 vaccination by next week

Bangladesh reported 1,788 new COVID-19 cases and 29 deaths of the disease on Sunday, bringing the tally to 462,407 and the death toll at 6,609, the Directorate General of Health Services (DGHS) said.

The official data showed that 13,737 samples were tested in the last 24 hours across Bangladesh.

The total number of recovered patients in the country stood at 378,172 including 2,287 new recoveries on Sunday, said the DGHS.

According to the official data, the COVID-19 fatality rate in Bangladesh is now 1.43 percent and the current recovery rate is 81.78 percent.Bangladesh recorded the highest daily new cases of 4,019 on July 2 and the highest number of deaths of 64 on June 30.

Bangladesh reported 1,788 new COVID-19 cases and 29 deaths of the disease on Sunday, bringing the tally to 462,407 and the death toll at 6,609, the Directorate General of Health Services (DGHS) said.

Bangladesh reported 1,788 new COVID-19 cases and 29 deaths of the disease on Sunday, bringing the tally to 462,407 and the death toll at 6,609, the Directorate General of Health Services (DGHS) said. The official data showed that 13,737 samples were tested in the last 24 hours across Bangladesh. The total number of recovered patients in the country stood at 378,172 including 2,287 new recoveries on Sunday, said the DGHS. According to the official data, the COVID-19 fatality rate in Bangladesh is now 1.43 percent and the current recovery rate is 81.78 percent.Bangladesh recorded the highest daily new cases of 4,019 on July 2 and the highest number of deaths of 64 on June 30.

Bangladesh's COVID-19 cases rise to 462,407, death toll reaches 6,609

For the second day in a row, the daily infections reported in the national capital were under 5,000 with 4,906 cases on Sunday while 6,325 patients recovered from the deadly disease. 
 
The number of deaths reported were 68, the lowest since November 5 which saw 66 fatalities. 
 
Delhi`s tally has risen to 5,66,648 and the toll has mounted to 9,066. As many as 131 Covid-related deaths were recorded on November 18, the highest till date. 
 
Delhi recorded 4,454 cases on Monday, 6,224 on Tuesday, 5,246 on Wednesday, 5,475 on Thursday, 5,482 on Friday and 4,998 on Saturday. 
 
The city had recorded its highest single-day spike of 8,593 cases on November 11. 
 
Meanwhile, the Covid-19 positivity rate in Delhi dropped to 7.64 on Sunday, the second-lowest this month so far. A day earlier, it stood at 7.24 per cent. The lowest positivity rate amid the third surge of the infection was recorded on October 23. 
 
On October 23, Delhi recorded a positivity rate of 6.98 per cent. It was 8.51 per cent on Friday, 8.65 per cent on Thursday and 8.49 per cent on Wednesday. 
 
A total of 64,186 tests were conducted in the last 24 hours, including 29,839 RT-PCR and 34,347 Rapid Antigen Test, according to a bulletin by the Delhi Health Department. 
 
The capital city had reported conducting 69,051 tests, the highest till date, on Saturday. 
 
The number of Covid containment zones in Delhi rose to 5,441 on Sunday from 5,331 on Saturday. 
 
Currently, 8,243 out of 18,661 Covid beds are occupied in hospitals, 465 out of 7,942 beds in the dedicated Covid Care Centres and 140 out of 562 beds in the dedicated Covid Health Centres. Over 21,337 people are in home isolation.

For the second day in a row, the daily infections reported in the national capital were under 5,000 with 4,906 cases on Sunday while 6,325 patients recovered from the deadly disease.

For the second day in a row, the daily infections reported in the national capital were under 5,000 with 4,906 cases on Sunday while 6,325 patients recovered from the deadly disease. The number of deaths reported were 68, the lowest since November 5 which saw 66 fatalities. Delhi`s tally has risen to 5,66,648 and the toll has mounted to 9,066. As many as 131 Covid-related deaths were recorded on November 18, the highest till date. Delhi recorded 4,454 cases on Monday, 6,224 on Tuesday, 5,246 on Wednesday, 5,475 on Thursday, 5,482 on Friday and 4,998 on Saturday. The city had recorded its highest single-day spike of 8,593 cases on November 11. Meanwhile, the Covid-19 positivity rate in Delhi dropped to 7.64 on Sunday, the second-lowest this month so far. A day earlier, it stood at 7.24 per cent. The lowest positivity rate amid the third surge of the infection was recorded on October 23. On October 23, Delhi recorded a positivity rate of 6.98 per cent. It was 8.51 per cent on Friday, 8.65 per cent on Thursday and 8.49 per cent on Wednesday. A total of 64,186 tests were conducted in the last 24 hours, including 29,839 RT-PCR and 34,347 Rapid Antigen Test, according to a bulletin by the Delhi Health Department. The capital city had reported conducting 69,051 tests, the highest till date, on Saturday. The number of Covid containment zones in Delhi rose to 5,441 on Sunday from 5,331 on Saturday. Currently, 8,243 out of 18,661 Covid beds are occupied in hospitals, 465 out of 7,942 beds in the dedicated Covid Care Centres and 140 out of 562 beds in the dedicated Covid Health Centres. Over 21,337 people are in home isolation.

At 68, Delhi reports lowest coronavirus toll after November 5

After his visit to three vaccine development centres, Prime Minister Narendra Modi is on Monday scheduled to speak to three other teams involved in developing a Covid-19 vaccine. 
 
The PMO, in a tweet, said: "Tomorrow, on 30th November 2020, PM Narendra Modi will interact, via video conferencing, with three teams that are involved in developing a COVID-19 vaccine. The teams he will interact with are from Gennova Biopharma, Biological E and Dr Reddy`s." 
 
The first two are proceeding with developing their own vaccines, while Dr Reddy`s has tied up with Russia to conduct trials of its Sputnik vaccine. 
 
The Prime Minister had visited three cities on Saturday to conduct an extensive review of the vaccine development and manufacturing process, going to the Zydus Biotech Park in Ahmedabad, the Bharat Biotech in Hyderabad and the Serum Institute of India in Pune. 
 
Expressing pride in the fact that India`s indigenous vaccine development has progressed at such a rapid pace so far, he had stressed that India considers vaccines as not only vital to good health but also as a global good, and it is India`s duty to assist other countries, including the nations in the neighbourhood, in the collective fight against the virus. 
 
Modi asked the scientists to express their free and frank opinion on how the country could further improve its regulatory process. The scientists also presented an overview of how they are also developing various new and repurposed drugs to better fight Covid-19. 
 
After visiting Pune, the Prime Minister had tweeted, "Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility." 
 
The Covidshield vaccine is being developed jointly by the Oxford University, AstraZeneca and the SII, which is the world`s largest vaccine manufacturer. 
 
Currently, the SII is producing around 50-60 million doses which would be scaled up to to 100 million by January 2021, SII CEO Adar Poonawalla told the media.

After his visit to three vaccine development centres, Prime Minister Narendra Modi is on Monday scheduled to speak to three other teams involved in developing a Covid-19 vaccine.

After his visit to three vaccine development centres, Prime Minister Narendra Modi is on Monday scheduled to speak to three other teams involved in developing a Covid-19 vaccine. The PMO, in a tweet, said: "Tomorrow, on 30th November 2020, PM Narendra Modi will interact, via video conferencing, with three teams that are involved in developing a COVID-19 vaccine. The teams he will interact with are from Gennova Biopharma, Biological E and Dr Reddy`s." The first two are proceeding with developing their own vaccines, while Dr Reddy`s has tied up with Russia to conduct trials of its Sputnik vaccine. The Prime Minister had visited three cities on Saturday to conduct an extensive review of the vaccine development and manufacturing process, going to the Zydus Biotech Park in Ahmedabad, the Bharat Biotech in Hyderabad and the Serum Institute of India in Pune. Expressing pride in the fact that India`s indigenous vaccine development has progressed at such a rapid pace so far, he had stressed that India considers vaccines as not only vital to good health but also as a global good, and it is India`s duty to assist other countries, including the nations in the neighbourhood, in the collective fight against the virus. Modi asked the scientists to express their free and frank opinion on how the country could further improve its regulatory process. The scientists also presented an overview of how they are also developing various new and repurposed drugs to better fight Covid-19. After visiting Pune, the Prime Minister had tweeted, "Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility." The Covidshield vaccine is being developed jointly by the Oxford University, AstraZeneca and the SII, which is the world`s largest vaccine manufacturer. Currently, the SII is producing around 50-60 million doses which would be scaled up to to 100 million by January 2021, SII CEO Adar Poonawalla told the media.

PM Modi to interact with more teams of Covid-19 vaccine developers

Elite runners take part in Delhi marathon despite COVID-19 and pollution concerns

More than 150 people have been arrested in central London after anti-lockdown protestors clashed with the local police while they were raising their voices against coronavirus lockdown in the UK.

The Metropolitan Police department said nearly 155 arrests have been made till now breaching coronavirus regulations, assaulting a police officer and possession of drugs.

Also read|&nbsp;<a href="https://www.wionews.com/world/at-least-60-arrested-in-anti-lockdown-protests-in-london-346127">At least 60 arrested in anti-lockdown protests in London</a>

These protests broke off in the capital city after it was announced that tier 3 lockdown measures will be brought in after December 02. The demonstrators walked&nbsp;

Protestors kept chanting "freedom" as they marched through Oxford Street and nearby Marble Arch while the police department asked the participants to leave. This demonstration also caused disruptions in traffic.

The Met argued that the demonstration was illegal as the country is still under a lockdown, which restricts the movement of people around the city, especially huge gatherings.

Also read|&nbsp;<a href="https://www.wionews.com/world/britons-to-plant-trees-to-mark-queen-elizabeths-70-years-on-throne-346146">Britons to plant trees to mark Queen Elizabeth's 70 years on throne</a>

Traffic on and around Regent Street was disrupted for long hours as the police tried to arrest more people protesting against Boris Johnson's government. The police also used green smoke to contain the protestors around Carnaby Street and disperse crowds near the Piccadilly Circus.

Protestors complained about police brutality with many claiming they were forced on the ground and were rushed out of every spot. Some locals who were passing by from the areas also complained of being targetted by the police, even though they were not a part of the protest.

"Protest is not currently a permitted exemption to the prohibition on gatherings under the current coronavirus regulations," the Met said in a statement. "Strict regulations have been introduced by the government nationally to help prevent the spread of coronavirus. This means that anyone gathering for protest risks enforcement action by officers."

Home Secretary Priti Patel said, "We've seen our police officers yet again do incredible work to ensure that they help to stop the spread of this awful virus. The people that are protesting today have been protesting for many months, and we’ve seen this over successive weekends.

"We ask everybody to be conscientious – we all know the regulations and the guidance, we have brought these measures in to save lives and to prevent preventable deaths."

More than 150 people have been arrested in central London after anti-lockdown protestors clashed with the local police while they were raising their voices against coronavirus lockdown in the UK.

More than 150 people have been arrested in central London after anti-lockdown protestors clashed with the local police while they were raising their voices against coronavirus lockdown in the UK. The Metropolitan Police department said nearly 155 arrests have been made till now breaching coronavirus regulations, assaulting a police officer and possession of drugs. Also read| At least 60 arrested in anti-lockdown protests in London These protests broke off in the capital city after it was announced that tier 3 lockdown measures will be brought in after December 02. The demonstrators walked Protestors kept chanting "freedom" as they marched through Oxford Street and nearby Marble Arch while the police department asked the participants to leave. This demonstration also caused disruptions in traffic. The Met argued that the demonstration was illegal as the country is still under a lockdown, which restricts the movement of people around the city, especially huge gatherings. Also read| Britons to plant trees to mark Queen Elizabeth's 70 years on throne Traffic on and around Regent Street was disrupted for long hours as the police tried to arrest more people protesting against Boris Johnson's government. The police also used green smoke to contain the protestors around Carnaby Street and disperse crowds near the Piccadilly Circus. Protestors complained about police brutality with many claiming they were forced on the ground and were rushed out of every spot. Some locals who were passing by from the areas also complained of being targetted by the police, even though they were not a part of the protest. "Protest is not currently a permitted exemption to the prohibition on gatherings under the current coronavirus regulations," the Met said in a statement. "Strict regulations have been introduced by the government nationally to help prevent the spread of coronavirus. This means that anyone gathering for protest risks enforcement action by officers." Home Secretary Priti Patel said, "We've seen our police officers yet again do incredible work to ensure that they help to stop the spread of this awful virus. The people that are protesting today have been protesting for many months, and we’ve seen this over successive weekends. "We ask everybody to be conscientious – we all know the regulations and the guidance, we have brought these measures in to save lives and to prevent preventable deaths."

London: More than 150 arrested in anti-lockdown protests

covid-19-0

Covid 19, News on Covid 19, stories on Covid 19, articles on Covid 19, Covid 19 stories at Wion, Covid 19 news, Covid 19 latest news

covid 19-0